Cerbios-Pharma Successfully Passes a General FDA cGMP Inspection
It is with pleasure that we announce that on Friday the 27th of April 2018, Cerbios-Pharma SA (from now on CERBIOS) successfully passed a general FDA GMP inspection.
Originally, the inspection was scheduled to last five days.
Due to the excellent results, the inspector decided to close the audit in the middle of the fifth day, without issuing any 483 observation.
“Since I joined CERBIOS in 2009, this is the third FDA inspection with no 483” says Gabriel Haering, CEO.
“This is the confirmation that our cGMP system is state-of-the-art and compliant with the most recent guidelines and validates our strategy of having an excellent system in place serving our partners world-wide” .
To read more about it, please click on this link.